A Physician’s Take on the CLEAR Trial Data

Video

Brian Shimkus, MD, shares his opinion of data on lenvatinib and pembrolizumab from the CLEAR trial.

Tom Powles, MBBS, MRCP, MD: Hi, I'm Tom Powles. I'm an oncologist from London. I look after patients with urology cancers, particularly bladder and kidney cancer, which we're talking about today. Brian, would you like to introduce yourself?

Brian Shimkus, MD: Yes. I'm Brian Shimkus. I'm a physician in Austin, Texas; private practice in a multi-specialty group. I don't specialize in any particular kind of cancer, but I enjoy genitourinary cancers and work closely with a very large group close to us. I've always been fond of treating renal cell carcinoma.

Tom Powles, MBBS, MRCP, MD: Brian, we just saw Bob Watson present the CLEAR data published in New England Journal [of Medicine]. There's been a later data cut more recently. The data looked impressive, with the response rate above 70%. The hazard ratio for PFS in the 0.39, I think, and the OS survival data significant at about 0.70. The total RB profile was okay. I think these combinations are challenging to give, more challenging than the single agent therapy, certainly. What was your take on the data overall in the paper?

Brian Shimkus, MD: I think it's amazing. If you look back, I've been practicing for about 20 years and going from renal cell carcinoma as a disease with interleukin therapy as the only option to something where we have all of these options, and now can decide how we want to treat people based on side effect profiles. It really gives them a bright outcome now. I've gone from treating people with single agents to getting better at treatment with multi-agent therapy. I think that really is the key here, as I see in this study. That's one of the big take-away points, is that the better you get at this, the more experience you have with multi-agent therapy, the better your patients are going to do. It becomes critical to understand how best to use these drugs, not just knowing which drugs are available.

Transcript edited for clarity.

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Related Content
The biomarker analysis in CHECKMATE-426 showed that pembrolizumab plus sunitinib therapy is associated with positive outcomes with angiogenesis in RCC.

Pembrolizumab/Axitinib Improves Survival vs Responses in Advanced RCC

Tim Cortese
August 1st 2025
Article

The biomarker analysis in CHECKMATE-426 showed that pembrolizumab plus sunitinib therapy is associated with positive outcomes with angiogenesis in RCC.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer

Roman Fabbricatore
July 24th 2025
Article

A genitourinary oncologist explained that KIM-1 can be used to diagnose, risk-stratify, and detect disease and monitor disease treatment in patients with kidney cancers.

Neoantigen Vaccines Are Leading to a Personalized Frontier in RCC Immunotherapy

Neoantigen Vaccines Are Leading to a Personalized Frontier in RCC Immunotherapy

Ashling Wahner
July 20th 2025
Article

David A. Braun, MD, PhD, discusses how neoantigen vaccines are redefining RCC treatment, with the potential to activate potent, lasting T-cell activity.